Relevant bibliographies by topics / Pyridopyrimidinic inhibitors / Journal articles
To see the other types of publications on this topic, follow the link: Pyridopyrimidinic inhibitors.

Journal articles on the topic 'Pyridopyrimidinic inhibitors'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 44 journal articles for your research on the topic 'Pyridopyrimidinic inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Du, Xi Hhua, and Wen Chang Zhuang. "Neural Network Model for Predicting Anticancer Activity of Pyridopyrimidines Derivatives." Advanced Materials Research 905 (April 2014): 96–100. http://dx.doi.org/10.4028/www.scientific.net/amr.905.96.

Full text
Abstract:
Molecular structures of pyridopyrimidines derivatives as known as dihydrofolate reductase (DHFR) inhibitors were investigated by using the neural network method. Based on the molecular connectivity, molecular connectivity index and molecular electronegativity distance vectors of 32 pyridopyrimidine derivatives were obtained. Among these parameters, three optimized structural parameters 1χ3χ and M17 as the input neurons of the artificial neural network were selected by step-wise regression. Then a 3:4:1 network architecture was employed and a satisfying neural network model for predicting antic
APA, Harvard, Vancouver, ISO, and other styles
2

Rosse, Gerard. "Pyridopyrimidines as Inhibitors of Hepatitis C Virus." ACS Medicinal Chemistry Letters 5, no. 3 (2013): 226–27. http://dx.doi.org/10.1021/ml4004149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zheng, Guo Zhu, Chih-Hung Lee, John K. Pratt, et al. "Pyridopyrimidine analogues as novel adenosine kinase inhibitors." Bioorganic & Medicinal Chemistry Letters 11, no. 16 (2001): 2071–74. http://dx.doi.org/10.1016/s0960-894x(01)00375-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Zhicai, John C. Hartnett, Lou Anne Neilson, et al. "Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors." Bioorganic & Medicinal Chemistry Letters 18, no. 4 (2008): 1274–79. http://dx.doi.org/10.1016/j.bmcl.2008.01.054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Slivka, Mikhail V., and Natalia I. Korol. "Condensed Pyridopyrimidines and Pyridopyrazines Containing a Bridgehead Nitrogen Atom: Synthesis, Chemical Properties and Biological Activity." Current Organic Chemistry 25, no. 12 (2021): 1429–40. http://dx.doi.org/10.2174/1385272825666210525154330.

Full text
Abstract:
The investigation of effective and green synthetic routes to approach to novel fused heterocycles with pyridopyrimidine and pyridopyrazine scaffolds stirs up broad interest from scientists as they are capable of providing valuable properties such as anticancer and antimicrobial activities and they are proved γ-secretase modulators, polymers, and corrosion inhibitors. This causes a steady increase in the number of publications on titled condensed systems. The present review article summarizes recent literature data from 2010 to 2020 on the methods of synthesis, chemical transformations and biol
APA, Harvard, Vancouver, ISO, and other styles
6

Zheng, Guo Zhu, and et al et al. "ChemInform Abstract: Pyridopyrimidine Analogues as Novel Adenosine Kinase Inhibitors." ChemInform 32, no. 45 (2010): no. http://dx.doi.org/10.1002/chin.200145170.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cowart, Marlon, Chih-Hung Lee, Gregory A. Gfesser, et al. "Structure–activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors." Bioorganic & Medicinal Chemistry Letters 11, no. 1 (2001): 83–86. http://dx.doi.org/10.1016/s0960-894x(00)00602-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Andrews, Logan D., Timothy R. Kane, Paola Dozzo, et al. "Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase." Journal of Medicinal Chemistry 62, no. 16 (2019): 7489–505. http://dx.doi.org/10.1021/acs.jmedchem.9b00625.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Labadie, Sharada, Kathy Barrett, Wade S. Blair, et al. "Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors." Bioorganic & Medicinal Chemistry Letters 23, no. 21 (2013): 5923–30. http://dx.doi.org/10.1016/j.bmcl.2013.08.082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Guiles, Joseph W., Andras Toro, Urs A. Ochsner, and James M. Bullard. "Development of 4H-pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors." Organic and Medicinal Chemistry Letters 2, no. 1 (2012): 5. http://dx.doi.org/10.1186/2191-2858-2-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Zhang, Jun-Peng, Jie Huang, Chao Liu, et al. "Discovery of a series of pyridopyrimidine derivatives as potential topoisomerase I inhibitors." Chinese Chemical Letters 25, no. 7 (2014): 1025–28. http://dx.doi.org/10.1016/j.cclet.2014.05.048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Cockerill, Stuart, Colin Stubberfield, Jeremy Stables, et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2." Bioorganic & Medicinal Chemistry Letters 11, no. 11 (2001): 1401–5. http://dx.doi.org/10.1016/s0960-894x(01)00219-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Zheng, Guo Zhu, Yue Mao, Chih-Hung Lee, et al. "Adenosine kinase inhibitors: polar 7-Substitutent of pyridopyrimidine derivatives improving their locomotor selectivity." Bioorganic & Medicinal Chemistry Letters 13, no. 18 (2003): 3041–44. http://dx.doi.org/10.1016/s0960-894x(03)00642-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Kots, A. Y., B. K. Choi, M. E. Estrella-Jimenez, et al. "Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea." Proceedings of the National Academy of Sciences 105, no. 24 (2008): 8440–45. http://dx.doi.org/10.1073/pnas.0803096105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Tanifum, Eric A., Alexander Y. Kots, Byung-Kwon Choi, Ferid Murad, and Scott R. Gilbertson. "Novel pyridopyrimidine derivatives as inhibitors of stable toxin a (STa) induced cGMP synthesis." Bioorganic & Medicinal Chemistry Letters 19, no. 11 (2009): 3067–71. http://dx.doi.org/10.1016/j.bmcl.2009.04.024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Gfesser, Gregory A., Erol K. Bayburt, Marlon Cowart, et al. "Synthesis and structure-activity relationships of 5-heteroatom-substituted pyridopyrimidines as adenosine kinase inhibitors." European Journal of Medicinal Chemistry 38, no. 3 (2003): 245–52. http://dx.doi.org/10.1016/s0223-5234(03)00019-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Ribble, Wendy, Walter E. Hill, Urs A. Ochsner, et al. "Discovery and Analysis of 4H-Pyridopyrimidines, a Class of Selective Bacterial Protein Synthesis Inhibitors." Antimicrobial Agents and Chemotherapy 54, no. 11 (2010): 4648–57. http://dx.doi.org/10.1128/aac.00638-10.

Full text
Abstract:
ABSTRACT Bacterial protein synthesis is the target for numerous natural and synthetic antibacterial agents. We have developed a poly(U) mRNA-directed aminoacylation/translation protein synthesis system composed of phenyl-tRNA synthetases, ribosomes, and ribosomal factors from Escherichia coli. This system, utilizing purified components, has been used for high-throughput screening of a small-molecule chemical library. We have identified a series of compounds that inhibit protein synthesis with 50% inhibitory concentrations (IC50s) ranging from 3 to 14 μM. This series of compounds all contained
APA, Harvard, Vancouver, ISO, and other styles
18

Krapf, Michael K., Jennifer Gallus, Sahel Vahdati, and Michael Wiese. "New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold." Journal of Medicinal Chemistry 61, no. 8 (2018): 3389–408. http://dx.doi.org/10.1021/acs.jmedchem.7b01012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Saurat, Thibault, Frédéric Buron, Nuno Rodrigues, et al. "Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors." Journal of Medicinal Chemistry 57, no. 3 (2014): 613–31. http://dx.doi.org/10.1021/jm401138v.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Cockerill, Stuart, and et al et al. "ChemInform Abstract: Indazolylamino Quinazolines and Pyridopyrimidines as Inhibitors of the EGFr and C-erbB-2." ChemInform 32, no. 37 (2010): no. http://dx.doi.org/10.1002/chin.200137154.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Ren, Li, Kateri A. Ahrendt, Jonas Grina, et al. "The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase." Bioorganic & Medicinal Chemistry Letters 22, no. 10 (2012): 3387–91. http://dx.doi.org/10.1016/j.bmcl.2012.04.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Al-Ashmawy, Aisha A. K., Fatma A. Ragab, Khaled M. Elokely та ін. "Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors". Bioorganic & Medicinal Chemistry Letters 27, № 14 (2017): 3117–22. http://dx.doi.org/10.1016/j.bmcl.2017.05.044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Crawford, Terry D., Chudi O. Ndubaku, Huifen Chen, et al. "Discovery of Selective 4-Amino-pyridopyrimidine Inhibitors of MAP4K4 Using Fragment-Based Lead Identification and Optimization." Journal of Medicinal Chemistry 57, no. 8 (2014): 3484–93. http://dx.doi.org/10.1021/jm500155b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Mizenina, Olga A., and Mark M. Moasser. "S-phase Inhibition of Cell Cycle Progression by a Novel Class of Pyridopyrimidine Tyrosine Kinase Inhibitors." Cell Cycle 3, no. 6 (2004): 794–801. http://dx.doi.org/10.4161/cc.3.6.899.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Basiri, Alireza, Vikneswaran Murugaiyah, Hasnah Osman, Raju Suresh Kumar, Yalda Kia, and Mohamed Ashraf Ali. "Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives." Bioorganic & Medicinal Chemistry 21, no. 11 (2013): 3022–31. http://dx.doi.org/10.1016/j.bmc.2013.03.058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Nixha, Arleta Rifati, Adem Ergun, Nahit Gencer, Oktay Arslan, and Mustafa Arslan. "Development of carbazole-bearing pyridopyrimidine-substituted urea/thiourea as polyphenol oxidase inhibitors: synthesis, biochemistry, and theoretical studies." Archives of Physiology and Biochemistry 125, no. 3 (2018): 263–69. http://dx.doi.org/10.1080/13813455.2018.1453523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Edwards, Philip D., Donald W. Andisik, Anne M. Strimpler, Bruce Gomes, and Paul A. Tuthill. "Nonpeptidic Inhibitors of Human Neutrophil Elastase. 7. Design, Synthesis, andin VitroActivity of a Series of Pyridopyrimidine Trifluoromethyl Ketones†." Journal of Medicinal Chemistry 39, no. 5 (1996): 1112–24. http://dx.doi.org/10.1021/jm950684z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Balupuri, Anand, Pavithra K. Balasubramanian, and Seung Joo Cho. "Computational Analysis of Pyridopyrimidine-based Polo Like Kinase 2 (PLK2) Inhibitors: Examining the Structural Basis for Anticancer Activity." Letters in Drug Design & Discovery 14, no. 5 (2017): 581–96. http://dx.doi.org/10.2174/1570180813666160831113237.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Eissa, Amal A. M., Kholoud F. M. Aljamal, Hany S. Ibrahim, and Heba Abdelrasheed Allam. "Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity." Bioorganic Chemistry 116 (November 2021): 105318. http://dx.doi.org/10.1016/j.bioorg.2021.105318.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Wolff, Nicholas C., Darren R. Veach, William P. Tong, William G. Bornmann, Bayard Clarkson, and Robert L. Ilaria. "PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia." Blood 105, no. 10 (2005): 3995–4003. http://dx.doi.org/10.1182/blood-2004-09-3534.

Full text
Abstract:
AbstractImatinib mesylate is highly effective in newly diagnosed chronic myeloid leukemia (CML), but BCR/ABL (breakpoint cluster region/abelson murine leukemia)–positive progenitors persist in most patients with CML treated with imatinib mesylate, indicating the need for novel therapeutic approaches. In this study, we have used the murine CML-like myeloproliferative disorder as a platform to characterize the pharmacokinetic, signal transduction, and antileukemic properties of PD166326, one of the most potent members of the pyridopyrimidine class of protein tyrosine kinase inhibitors. In mice w
APA, Harvard, Vancouver, ISO, and other styles
31

Nakayama, Kiyoshi, Haruko Kawato, Jun Watanabe, et al. "MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model." Bioorganic & Medicinal Chemistry Letters 14, no. 2 (2004): 475–79. http://dx.doi.org/10.1016/j.bmcl.2003.10.060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Cano, Céline, Olivier R. Barbeau, Christine Bailey, et al. "DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype." Journal of Medicinal Chemistry 53, no. 24 (2010): 8498–507. http://dx.doi.org/10.1021/jm100608j.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Fry, David W., James M. Nelson, Veronika Slintak, et al. "Biochemical and antiproliferative properties of 4-[Ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor." Biochemical Pharmacology 54, no. 8 (1997): 877–87. http://dx.doi.org/10.1016/s0006-2952(97)00242-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Littman, Susan Joy, Erik S. Knudsen, Agnieszka Witkiewicz, et al. "A phase II study of PD-0332991 in patients with advanced hepatocellular cancer." Journal of Clinical Oncology 31, no. 4_suppl (2013): 321. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.321.

Full text
Abstract:
321 Background: Hepatocellular carcinoma (HCC) is the 5th most common cancer worldwide and the 3rd most frequent cause of cancer-related mortality. Surgical resection & liver transplantation are the main curative options. Most patients present with advanced stage and poor liver function and are ineligible. Cytotoxic drugs give poor response rates and little benefit. The MKI sorafenib has been shown to significantly increase PFS and OS in advanced HCC in 2 rPhase 3 trials. PD-0332991 is an orally available, pyridopyrimidine-derived, selective inhibitor of CDK4/6, that results in the inhibit
APA, Harvard, Vancouver, ISO, and other styles
35

Abdelrehim, El-sayed M., and Doaa S. El-Sayed. "A New Synthesis of Poly Heterocyclic Compounds Containing [1,2,4]triazolo and [1,2,3,4]tetrazolo Moieties and their DFT Study as Expected Anti-cancer Reagents." Current Organic Synthesis 17, no. 3 (2020): 211–23. http://dx.doi.org/10.2174/1570179417666200226092516.

Full text
Abstract:
Background: 2-amino-3-cyanopyridines are good starting reagents that have been used in synthesis of many heterocyclic compounds such as pyridopyrimidines, [1,2,4]triazolo and [1,2,3,4] tetrazolo derivatives which have biological activities as anti-microbial and cytotoxic activities. Meanwhile [1,2,4]triazolo and [1,2,3,4]tetrazolo derivatives are well known to possess many physiological activities, such as anticancer , antifungal, muscle relaxant, hypnotic, anti-inflammatory, diuretic and antihypertensive activities. A broad class of heterocyclic compounds has been studied to demonstrate their
APA, Harvard, Vancouver, ISO, and other styles
36

Yousif, Mahmoud N. M., Abdel-Rahman B. A. El-Gazzar, and Mervat M. El-Enany. "Synthesis and Biological Evaluation of Pyrido(2,3-d)pyrimidines." Mini-Reviews in Organic Chemistry 17 (May 11, 2020). http://dx.doi.org/10.2174/1570193x17999200511010402.

Full text
Abstract:
: There are four types of pyridopyrimidines namely pyrido[2,3-d], pyrido[3,4-d], pyrido[4,3-d]pyrimidines, and pyrido[3,2- d]pyrimidines. Different methods of preparation of pyrido[2,3-d]pyrimidines are summarized. Synthesis of pyrido[2,3-d]pyrimidines can be from pyrimidines derivatives or pyridine derivatives. We can start from pyrimidine derivatives and build pyridine ring. 5,7- Diphenylpyrido[2,3-d]pyrimidines 3 and 4 were obtained by the reaction of 6-aminouracil (1) with α,β-unsaturated ketone. 6-Amino-1,3- dimethyluracil 10 was reacted with equimolar amount of Mannich bases 11a-c under
APA, Harvard, Vancouver, ISO, and other styles
37

Zheng, Guo Zhu, and et al et al. "Adenosine Kinase Inhibitors: Polar 7-Substituent of Pyridopyrimidine Derivatives Improving Their Locomotor Selectivity." ChemInform 34, no. 51 (2003). http://dx.doi.org/10.1002/chin.200351146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Gfesser, Gregory A., Erol K. Bayburt, Marlon Cowart, et al. "Synthesis and Structure—Activity Relationships of 5-Heteroatom-Substituted Pyridopyrimidines as Adenosine Kinase Inhibitors." ChemInform 34, no. 31 (2003). http://dx.doi.org/10.1002/chin.200331176.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Bullard, James M., Joseph W. Guiles, Andras Toro, and Urs Ochsner. "Structure‐activity optimization of 4H‐pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors." FASEB Journal 25, S1 (2011). http://dx.doi.org/10.1096/fasebj.25.1_supplement.967.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Panchabhai, Vivek, Parag Ingole, and S. Butle. "Design, Synthesis and Antibacterial Studies of Some New Pyridopyrimidine Derivatives as Biotin Carboxylase Inhibitors." Bulletin of Faculty of Pharmacy, Cairo University, January 5, 2021, 0. http://dx.doi.org/10.21608/bfpc.2019.10149.1017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Tanifum, Eric A., Alexander Y. Kots, Byung-Kwon Choi, Ferid Murad, and Scott R. Gilbertson. "ChemInform Abstract: Novel Pyridopyrimidine Derivatives as Inhibitors of Stable Toxin a (STa) Induced cGMP Synthesis." ChemInform 40, no. 42 (2009). http://dx.doi.org/10.1002/chin.200942205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Siddharth J., Modi, Modh Dharti H., and Kulkarni Vithal M. "Insights into the structural features of anticancer 1,6-naphthyridines and pyridopyrimidines as VEGFR-2 inhibitors: 3D-QSAR study." Journal of Applied Pharmaceutical Science, October 4, 2020. http://dx.doi.org/10.7324/japs.2020.10101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

"A novel class of pyridopyrimidine tyrosine kinase inhibitors blocks cancer cells in the S-phase of the cell cycle." European Journal of Cancer 38 (November 2002): S50. http://dx.doi.org/10.1016/s0959-8049(02)80805-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Nakayama, Kiyoshi, and et al et al. "MexAB-OprM Specific Efflux Pump Inhibitors in Pseudomonas aeruginosa. Part 3. Optimization of Potency in the Pyridopyrimidine Series Through the Application of a Pharmacophore Model." ChemInform 35, no. 18 (2004). http://dx.doi.org/10.1002/chin.200418150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography